Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Amgen Epogen To Add Aplasia Warning, Brought In Line With J&J’s Procrit

  • News

Executive Summary

Amgen Epogen (epoetin alfa) will add a warning for pure red cell aplasia to its labeling after consulting with FDA

You may also be interested in...



Aranesp Related To Four Cases Of PRCA, Far Below Eprex Rate, Amgen Says

Amgen is reporting four cases of pure red cell aplasia in Aranesp (darbepoetin alfa) patients

Aranesp Related To Four Cases Of PRCA, Far Below Eprex Rate, Amgen Says

Amgen is reporting four cases of pure red cell aplasia in Aranesp (darbepoetin alfa) patients

J&J Eprex “Best Handling Practices” Program Aims To Reduce PRCA Cases

Johnson & Johnson is instituting a best handling practices program for Eprex to reduce pure red cell aplasia associated with the product

Table

View full table

Tags:
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS041986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By